Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Crohn's Disease

Crohn's Disease

Part of Inflammatory Bowel Disease

Subtypes of Crohn's Disease

Small bowel Crohn's disease 1

27 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Crohn's Disease

143 trials tracked for Crohn's Disease: 60 in phase 3 or 4 and 30 with published results. The most-cited published study has 909 citations.

143Trials tracked
60Phase 3 & 4
0Recruiting
30With published results
Phase distribution
Phase 4 5 Phase 3 55 Phase 2 42 Phase 1 8 Other / NA 33
  1. Phase 3 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease Completed · 909 cited
  2. Phase 4 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed · 602 cited
  3. Phase 3 Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease Completed · 209 cited
  4. Phase 3 Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease Completed · 207 cited
  5. Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease Completed · 190 cited
  6. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) Completed · 131 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease Completed · 83 cited
  2. Phase 4 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease Completed · 80 cited
  3. Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Completed · 61 cited
  4. Phase 3 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 Completed · 60 cited
  5. Phase 3 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) Completed · 59 cited
  6. Phase 3 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease Completed · 51 cited
  7. Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy Completed · 42 cited
  8. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Completed · 40 cited
  9. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) Completed · 40 cited
  10. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Completed · 40 cited
  11. Phase 3 Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease Completed · 25 cited
  12. Phase 4 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed · 24 cited
  13. Phase 3 Safety Study of Entocort for Children With Crohn's Disease Completed · 14 cited
  14. Phase 3 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies Completed · 14 cited
  15. Phase 3 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Completed · 13 cited
  16. Phase 3 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Completed · 13 cited
  17. Phase 3 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment Completed · 13 cited
  18. Phase 3 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease Completed · 12 cited
  19. Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed · 11 cited
  20. Phase 3 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Completed · 6 cited
  21. Phase 3 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Completed · 5 cited
  22. Phase 3 A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Completed · 4 cited
  23. Phase 3 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) Completed · 3 cited
  24. Phase 3 Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) Completed · 1 cited
  25. Phase 4 Centocor Microarray Study of Patients Completed
  26. Phase 3 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan Completed
  27. Phase 3 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease Completed
  28. Phase 3 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 Completed
  29. Phase 3 Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD Completed
  30. Phase 3 A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease Completed
  31. Phase 3 Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. Completed
  32. Phase 3 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) Completed
  33. Phase 3 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula Completed
  34. Phase 3 A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Completed
  35. Phase 3 A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease Completed
  36. Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease Completed
  37. Phase 3 Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease Completed
  38. Phase 3 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Completed
  39. Phase 3 Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) Completed
  40. Phase 3 Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease Completed
  41. Phase 3 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease Completed
  42. Phase 3 A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease Completed
  43. Phase 3 Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease Completed
  44. Phase 3 Mucosal Healing Study in Crohn's Disease (CD) Completed

Showing the 50 most-cited and recently-updated of 143 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Crohn's Disease: current evidence & treatments

Crohn's disease (CD) involves complex pathophysiological mechanisms including mucus-barrier dysfunction, ER stress, and microbial sensing, as shown by transcriptomic meta-analysis of 1,302 active, untreated human samples 1. Genetic studies have identified 619 independent association signals for inflammatory bowel disease (IBD) across 420 regions, accounting for 77-80% of SNP-based heritability 6. Oral microbiome analysis reveals significantly reduced Shannon diversity in CD patients compared to controls 10. Additionally, IgG glycan profiles can discriminate IBD from controls, with IBD patients showing accelerated biological aging 20. Neutrophil SIRL-1/IL-8 ratio has been evaluated as a diagnostic biomarker for IBD 17.

Several therapeutic options are available for CD. The FDA has approved adalimumab (Hadlima) for pediatric CD (ages 6 and older) 7 and ustekinumab (Stelara) for adult CD 1415. A Phase 3 trial of darvadstrocel for perianal fistulas showed a 48.8% combined remission rate but was not superior to placebo 3. In pediatric CD, exclusive enteral nutrition was superior to corticosteroids for inducing clinical remission (OR 1.72) and mucosal healing 13. Enteral nutrition therapy in a Chinese cohort achieved 62.5% remission in CD over 6 weeks 11. Upadacitinib showed a 94.1% remission rate at 26 weeks in a retrospective CD cohort 18. Guselkumab is under investigation in Phase 2/3 trials for moderately to severely active CD 25. The Mediterranean diet showed no significant advantage over control diets for inducing remission in IBD 4.

Diagnostic approaches include video capsule endoscopy (VCE) in children, which often requires endoscopic placement (25% of examinations) and has diagnostic utility for CD 21. Small bowel capsule endoscopy as initial investigation reduced the need for double-balloon enteroscopy in suspected small bowel CD 23. Risk factors for CD include childhood antibiotic use, which increases IBD risk (RR 1.42) and specifically CD risk (RR 1.59) 8. Cesarean section was not associated with IBD risk in a meta-analysis of over 13 million births 24. Pediatric IBD patients have increased risk of venous thromboembolism (RR 6.94) 22. Brain alterations in CD localize to emotional and interoceptive networks, with distinguishable phenotypes from ulcerative colitis 2.

Key drugs in the evidence

ustekinumab 3 adalimumab 2 upadacitinib 1 antibiotics 1 biologicals 1 azathioprine 1 5-ASA 1 mercaptopurine 1 aminosalicylates 1 vedolizumab 1

Latest findings

AI-generated synthesis of 20 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk
OB/GYN & Women's Health Meta-analysis
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk Does having a C-section raise your child's risk of inflammatory bowel disease?
This systematic review and meta-analysis evaluated the association between mode of delivery and risk of inflammatory bowel disease (IBD) in …
A review of over 13 million births found no link between C-sections and inflammatory bowel disease, easing concerns for parents.
Frontiers Apr 9, 2026
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Gastroenterology Phase III
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
CT.gov Mar 28, 2026
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Gastroenterology Phase IV
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
CT.gov Mar 27, 2026

Questions about Crohn's Disease

Do the new biomarkers in the study help diagnose Crohn's Disease?

The study identified three biomarkers (ARHGEF3, S100A8, RHOU) that show high diagnostic accuracy for ulcerative colitis, but their ability to diagnose Crohn's disease specifically was not established.

Full answer →
Are there new drugs for Crohn's Disease approved by the FDA?

Yes, the FDA has approved newer drugs for Crohn's disease, including Stelara (ustekinumab) and Hadlima (adalimumab), and selective IL-23 inhibitors are emerging as promising options.

Full answer →
Can enteral nutrition therapy help Crohn's Disease patients achieve remission?

Yes, enteral nutrition therapy can help Crohn's disease patients achieve remission, especially exclusive enteral nutrition (EEN) in children, with evidence also supporting partial enteral nutrition (PEN) combined with exclusion diets in adults.

Full answer →
How does gut bacteria diversity in Crohn's Disease compare to healthy people?

People with Crohn's disease typically have lower gut bacteria diversity and an altered microbial community compared to healthy individuals.

Full answer →
How does oral microbial diversity in Crohn's disease compare to people without the condition?

People with Crohn's disease have significantly lower oral microbial diversity compared to healthy individuals, with specific bacterial shifts and reduced butyrate metabolism.

Full answer →
See all 5 questions about Crohn's Disease →